Evaluating CJC-1295 pricing ('cjc prijs') in analytical research settings requires evaluating chemical purity, structural modification, and verified batch consistency. PX1 Research provides laboratory-grade CJC-1295 variants with full analytical documentation for high-precision in vitro and preclinical investigation.
Evaluating CJC-1295 pricing ('cjc prijs') in analytical research settings requires evaluating chemical purity, structural modification, and verified batch consistency. PX1 Research provides laboratory-grade CJC-1295 variants with full analytical documentation for high-precision in vitro and preclinical investigation.
Evaluating CJC-1295 pricing ('cjc prijs') requires examining synthesis purity, chemical modification, and analytical verification standards. The true cost of research-grade CJC-1295 reflects high-performance liquid chromatography (HPLC) testing, mass spectrometry validation, endotoxin screening, and ISO 17025 laboratory quality controls necessary for reproducible preclinical experimental outcomes.
When principal investigators evaluate supplier costs, the unit price per milligram must be weighted against the rigor of quality assurance. Low-cost reagents that lack third-party verification frequently introduce unquantified impurities, sequence truncation artifacts, or residual solvent contaminants into experimental models. These variables undermine data integrity in cell culture assays or animal studies. Institutional researchers seeking dependable candidates can review our complete catalog of research peptides to compare verified sequences.
CJC-1295 is a synthetic 29-amino-acid tetrasubstituted peptide analog of Growth Hormone-Releasing Hormone (GHRH). The base sequence incorporates targeted amino acid substitutions at positions 2, 8, 15, and 27 (D-Ala2, Gln8, Ala15, and Leu27). These modifications confer enhanced enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV) cleavage compared to native GHRH(1-29).
In chemical synthesis, two distinct formulations of CJC-1295 exist, directly influencing both experimental application and procurement economics:
1. CJC-1295 Without DAC (also designated Mod GRF 1-29): A truncated 29-amino-acid peptide that mimics the physiological pulsatile stimulation of endogenous GHRH. Researchers can inspect characterization metrics for CJC-1295 No DAC for acute receptor signaling assays.
2. CJC-1295 With DAC (Drug Affinity Complex): Features a bi-functional maleimide derivative linker attached to the C-terminus lysine residue. This reactive affinity moiety forms a covalent bond with endogenous circulating albumin via Lys34 upon exposure in bio-fluid media. This dramatically extends the elimination half-life in preclinical models from minutes to several days. Details regarding CJC-1295 DAC highlight how this modification alters molecular weight and synthesis complexity, which accounts for variance in material valuation.
In vitro and animal models demonstrate that CJC-1295 functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a G-protein coupled receptor expressed primarily on anterior pituitary somatotrophs. Activation of GHRHR initiates the Gαs signaling cascade, stimulating intracellular adenylate cyclase activity and elevating cyclic adenosine monophosphate (cAMP) concentrations.
Preclinical studies suggest that elevated cAMP triggers protein kinase A (PKA) activation, leading to downstream phosphorylation of CREB (cAMP response element-binding protein). This transcriptional cascade increases mRNA encoding growth hormone (GH) while opening L-type voltage-gated calcium channels to stimulate exocytosis of stored GH granules.
Because CJC-1295 preserves the physiological feedback architecture mediated by somatostatin (SRIF), preclinical models show sustained, physiological pulsatility rather than unmitigated, tonic secretion when non-DAC formulations are utilized. Experimental assays utilizing research peptides targeting the GHRH axis allow investigators to map precise somatotroph receptor density and signaling kinetics under controlled laboratory conditions.
When designing comparative secretagogue protocols, researchers frequently evaluate CJC-1295 alongside distinct classes of growth hormone secretagogues (GHS) to observe synergistic or divergent pathways in vitro.
While CJC-1295 acts directly upon the GHRH receptor, ghrelin receptor agonists target the Growth Hormone Secretagogue Receptor 1a (GHSR-1a). For example, co-incubating GHRH analogs with Ipamorelin in pituitary tissue cultures demonstrates a marked synergistic release of GH without parallel elevations in cortisol or prolactin. Alternatively, structural comparisons can be drawn against Tesamorelin, a trans-3-hexenoic acid modified GHRH(1-44) sequence engineered for distinct metabolic receptor stability, or GHRP-6, a hexapeptide ghrelin mimetic widely utilized to probe ghrelinergic receptor kinetics.
Understanding how GHRHR agonists interact alongside GHSR-1a ligands provides critical context when establishing multifactorial experimental matrices in endocrinology research.
The primary factor determining legitimate CJC-1295 valuation ('cjc prijs') is the depth of analytical validation performed prior to distribution. Unverified peptide materials frequently suffer from incomplete deprotection during solid-phase peptide synthesis (SPPS), deletion sequences, or heavy metal contamination from TFA (trifluoroacetic acid) counter-ion salts.
PX1 Research establishes rigorous quality benchmarks for every production lot manufactured in US-based, GMP-compliant facilities:
- Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Establishes chemical purity levels exceeding 98%. RP-HPLC retention times confirm sequence uniformity and quantify residual synthesis artifacts.
- Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact molecular weight and verifies structural sequence fidelity relative to theoretical mass calculations.
- Endotoxin Quantification: Limulus Amebocyte Lysate (LAL) testing guarantees endotoxin levels below 0.01 EU/mg, preventing unwanted inflammatory responses in cellular assays.
- Lot-Specific Certificate of Analysis (COA): Every vial is indexed to a publicly accessible COA from an independent ISO 17025 accredited laboratory. Institutional procurement teams can verify these metrics directly within our research library.
Proper handling and reconstitution protocols are vital to preserve peptide secondary structure and prevent aggregation or cleavage during experimental manipulation. CJC-1295 is supplied as a lyophilized (freeze-dried) cake under inert nitrogen atmosphere.
Reconstitution Procedures for Analytical Work:
1. Equilibration: Allow the lyophilized vial to reach room temperature (20°C–25°C) before reconstitution to prevent moisture condensation within the container.
2. Solvent Selection: Reconstitute using sterile Bacteriostatic Water (0.9% benzyl alcohol) for multi-use analytical protocols or sterile 0.9% Sodium Chloride / Water for Injection (WFI) for sensitive cell culture media.
3. Solubilization: Direct the solvent stream down the inner glass wall of the vial rather than forcefully spraying onto the lyophilized powder. Gently swirl the vial in a circular motion. Never vortex or vigorously shake peptide solutions, as mechanical shear stress induces protein denaturation and irreversible aggregation.
4. Concentration Verification: Calculate final working concentration (mg/mL) based on solvent volume to ensure accurate micro-pipetting during serial dilution assays.
Maintaining chemical integrity across extended experimental timelines requires strict temperature control:
- Lyophilized Form: Stable at -20°C for up to 24 months. For long-term archival storage (>24 months), maintain at -80°C in a desiccated environment to minimize hydrolytic degradation.
- Reconstituted Solutions: Liquid aliquots should be stored at 2°C to 8°C and utilized within 14 to 30 days depending on the preservative system (e.g., benzyl alcohol concentration).
- Freeze-Thaw Avoidance: If long-term liquid storage is required, aliquot reconstituted solution into single-use micro-centrifuge tubes and freeze at -80°C. Repeated freeze-thaw cycles cause physical stress, leading to peptide cleavage and precipitation.
Procurement officers and lab managers evaluating supplier cost structures ('cjc prijs') must consider the total cost of research disruption caused by inconsistent reagent quality. Overseas suppliers often omit lot-specific testing, leading to variable binding affinities and unexplainable data outliers between experimental runs.
PX1 Research mitigates risk through transparent domestic manufacturing and logistics:
- USA-Manufactured Compounds: All synthesis and purification steps occur within regulated US facilities operating under strict ISO quality standards.
- Rapid Domestic Dispatch: Orders ship directly from fulfillment hubs in California and Arizona, providing same-day dispatch (Monday–Friday) to eliminate customs delays and thermal exposure during transit.
- Scaled Analytical Sourcing: Institutional accounts requiring custom synthesis batches or bulk volume procurement can coordinate with our dedicated account team via our wholesale procurement portal.
By prioritizing batch-to-batch consistency, rigorous HPLC/MS documentation, and low endotoxin limits, PX1 Research delivers maximum scientific value for research investments.
What primary factors determine CJC-1295 pricing ('cjc prijs') in research supply?
CJC-1295 pricing reflects synthesis complexity (DAC vs. No DAC), purity thresholds (>98%), third-party analytical verification (HPLC and Mass Spectrometry), endotoxin testing, and GMP-compliant domestic manufacturing standards.
What is the structural difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC includes a Drug Affinity Complex maleimide linker at the C-terminus that covalently binds to circulating albumin, extending half-life in animal models. CJC-1295 No DAC (Mod GRF 1-29) lacks this linker and exhibits a shorter, pulsatile pharmacokinetic profile.
Is CJC-1295 approved for human consumption or therapeutic use?
No. CJC-1295 is strictly a research peptide supplied exclusively for laboratory, in vitro, and preclinical experimental research. It is not approved by the FDA for human use, administration, or medical treatment.
How does PX1 Research verify the purity of CJC-1295 lots?
Every lot undergoes independent ISO 17025 laboratory testing using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity assessment and Electrospray Ionization Mass Spectrometry (ESI-MS) for molecular weight verification, accompanied by full COA documentation.
What solvent is recommended for reconstituting CJC-1295 for laboratory work?
Bacteriostatic Water (0.9% benzyl alcohol) or sterile laboratory-grade Water for Injection (WFI) is recommended, depending on the specific requirements of the downstream in vitro or analytical assay.
What endotoxin thresholds are guaranteed for PX1 Research peptides?
PX1 Research enforces strict endotoxin screening via Limulus Amebocyte Lysate (LAL) assays, ensuring levels remain under 0.01 EU/mg to prevent cellular inflammation or confounding assay variables.
How should CJC-1295 be stored upon delivery to the laboratory?
Lyophilized CJC-1295 should be stored at -20°C for short-to-medium term storage, or -80°C for long-term storage. Reconstituted liquid aliquots must be kept at 2°C–8°C and protected from repeated freeze-thaw cycles.
Does PX1 Research offer bulk pricing for institutional research laboratories?
Yes. Institutional laboratories requiring scaled quantities or multi-gram custom lots can access bulk procurement rates and batch reserve programs through the PX1 Research wholesale portal.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.